Category - Developments

Developments

Profound Medical in collaboration with Siemens Healthineers to expand access to the TULSA procedure to treat prostate disease

Profound Medical (NASDAQ:PROF; TSX:PRN) announced a non-exclusive collaboration with Siemens Healthineers (XETRA:SHL) aimed at laying the groundwork for Profound to begin marketing a complete therapeutics solution...

February 28, 2024

Developments

iBio sells preclinical PD-1 agonist antibody program to Otsuka

iBio (NYSEA:IBIO) has sold assets related to its early-stage programmed cell death protein 1 (PD-1 ) agonist program to Otsuka Pharmaceutical. Under the terms of the accord, iBio received an upfront payment of $1.0...

February 27, 2024

Developments

Studies validate advantages of administering drugs to pets via IntelGenx’s VetaFilm platform

IntelGenx (TSX:IGX; OTCQB:IGXT) announced positive results from a proof-of-concept study, conducted through a research collaboration with the University Prince Edward Island (UPEI), to assess the palatability, owner...

February 5, 2024

Developments

BioRestorative Therapies posts positive preliminary Phase 2 data for cLDD

BioRestorative Therapies (NASDAQ:BRTX) announced the public availability of a poster, presented yesterday at the Orthopaedic Research Society’s 2024 Annual Meeting, which describes preliminary 26 and 52 week blinded...

February 5, 2024

Developments

Japan Patent Office issues decision to grant patent for Anixa’s ovarian cancer vaccine

Anixa Biosciences (NASDAQ:ANIX) reported that its partner, Cleveland Clinic, received a “Decision to Grant” notice from the Japan Patent Office (JPO) for the patent application covering the company’s ovarian cancer...

January 23, 2024

Developments

Satisfied TULSA prostate cancer procedure patient discloses 5.2% stake in Profound Medical

In a 13G filed with the SEC today, accomplished businessman and founder of namesake transportation company Daseke (NADAQ:DSKE), Don Daseke, disclosed he has taken a 5.2% ownership stake in Profound Medical (NASDAQ:PROF)...

January 12, 2024

Developments

Sigyn outlines 2023 achievements, 2024 outlook

In a letter to shareholders to Sigyn Therapeutics’ (OTCQB:SIGY) shareholders, Jim Joyce, chairman and CEO, said as a small organization operating in a world with short-term expectations, the company has “not wavered...

January 8, 2024

Developments

IntelGenx enters VetaFilm development license agreements under new animal health partnership

IntelGenx (TSX:IGX; OTCQB:IGXT) entered into development and license agreements with a wholly owned subsidiary of Covenant Animal Health Partners, who will fund the development and manufacturing of a VetaFilm-based drug...

December 18, 2023

Developments Markets

Hepion reports restructuring and resignations; Brookline downgrades to hold and suspends target

Hepion Pharmaceuticals (NASDAQ:HEPA) announced a restructuring that, among other things, will suspend the enrollment of new patients in the Phase 2b ‘ASCEND-NASH’ clinical trial of its lead drug candidate, rencofilstat...

December 7, 2023

Developments

Anixa reports positive new data from Phase 1 breast cancer vaccine trial

Anixa Biosciences (NASDAQ:ANIX) and its partner, Cleveland Clinic, presented positive new results from the Phase 1 clinical trial of Anixa’s breast cancer vaccine at the 2023 San Antonio Breast Cancer Symposium (SABCS)...

December 7, 2023

Category - Developments

Profound Medical in collaboration with Siemens Healthineers to expand access to the TULSA procedure to treat prostate disease

iBio sells preclinical PD-1 agonist antibody program to Otsuka

Studies validate advantages of administering drugs to pets via IntelGenx’s VetaFilm platform

BioRestorative Therapies posts positive preliminary Phase 2 data for cLDD

Japan Patent Office issues decision to grant patent for Anixa’s ovarian cancer vaccine

Satisfied TULSA prostate cancer procedure patient discloses 5.2% stake in Profound Medical

Sigyn outlines 2023 achievements, 2024 outlook

IntelGenx enters VetaFilm development license agreements under new animal health partnership

Hepion reports restructuring and resignations; Brookline downgrades to hold and suspends target

Anixa reports positive new data from Phase 1 breast cancer vaccine trial

General

More